Connection

PARTOW KEBRIAEI to Immunosuppressive Agents

This is a "connection" page, showing publications PARTOW KEBRIAEI has written about Immunosuppressive Agents.
Connection Strength

0.378
  1. Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2017 Feb; 23(2):318-324.
    View in: PubMed
    Score: 0.087
  2. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 2016 Nov 15; 122(21):3316-3326.
    View in: PubMed
    Score: 0.085
  3. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009 Jul; 15(7):804-11.
    View in: PubMed
    Score: 0.052
  4. Graft loss attributed to possible transfusion-transmitted ehrlichiosis following cord blood stem cell transplant. Transpl Infect Dis. 2018 Aug; 20(4):e12899.
    View in: PubMed
    Score: 0.024
  5. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer. 2017 Sep 15; 123(18):3568-3575.
    View in: PubMed
    Score: 0.022
  6. Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol. 2017 05; 177(4):567-577.
    View in: PubMed
    Score: 0.022
  7. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis. Cancer. 2017 06 01; 123(11):2035-2042.
    View in: PubMed
    Score: 0.022
  8. Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports. J Med Case Rep. 2016 Jul 28; 10:209.
    View in: PubMed
    Score: 0.021
  9. Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study. Biol Blood Marrow Transplant. 2013 Mar; 19(3):474-80.
    View in: PubMed
    Score: 0.017
  10. Clofarabine ? fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant. 2011 Jun; 17(6):893-900.
    View in: PubMed
    Score: 0.014
  11. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia. 2007 Dec; 21(12):2540-4.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.